Skip to main content
. 2016 Oct 14;7(50):82876–82888. doi: 10.18632/oncotarget.12657

Figure 4. Dasatinib inhibits the growth of LYN-positive lung ADC xenografts.

Figure 4

A. H1975 cells were injected subcutaneously into nude mice. Dasatinib treatment began when the average tumor size reached ~100 mm3. Dasatinib was intraperitoneally injected for 2 weeks at either 10 mg·kg−1·day−1 or 20 mg·kg−1·day−1 (*, P < 0.05 vs. vehicle; #, P < 0.05 vs. dasatinib [10 mg]). B. H1975 xenografts from (A) were resected, and tumor weights were measured at the time of tumor harvest (bars, mean and SD; *, P < 0.05 vs. vehicle; #, P < 0.05 vs. dasatinib [10 mg]; white bar = 1 cm). C. Immunoprecipitation was performed with an LYN antibody on lysates from H1975 xenograft tumors, followed by immunoblotting with a cross-reactive pY416-Src antibody (◄).